Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20085797
Nelson AC, et al. (2010) AKT regulates BRCA1 stability in response to hormone signaling. Mol Cell Endocrinol 319, 129-42 20085797
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  BG-1, MCF-7 (breast cell), MDA-MB-231 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 serum inhibit treatment-induced increase
Akt_inhibitor_VIII serum inhibit treatment-induced increase
estradiol increase
LY294002 estradiol inhibit treatment-induced increase
IGF-1 increase
MG132 increase
LY294002 MG132 inhibit treatment-induced increase
bortezomib increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

T509-p - BRCA1 (human)
Modsite: LKRKRRPtsGLHPED SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): T509‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): T509‑p, BRCA1 (mouse): S502‑p, BRCA1 (rat): S503‑p

S694-p - BRCA1 (human)
Modsite: QTSKRHDsDTFPELk SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S694‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S694‑p, BRCA1 (mouse): S686‑p, BRCA1 (rat): S686‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry (in vitro), phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  BG-1, MCF-7 (breast cell), MDA-MB-231 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estradiol increase
IGF-1 increase
Downstream Regulation
Effect of modification (function):  protein stabilization